Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Christian Gossens

Mike Baker

Michael Lindemann

Shibeshih Mitiku Belachew

Christian Czech

Timothy Kilchenmann

Joerg Sprengel

Jörg Sprengel

Ignacio Fernandez Garcia

Florian Lipsmeier

Detlef Wolf

Kirsten Taylor

Luis Rafael Ibanez Alonso

Irene B Meier

Gregoire Henry Simon Pointeau

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Digital biomarker

Disclosed is a method for assessing a cognition and movement disease or disorder in a subject. In the method, a qualimetric activity parameter for cognition and/or fine motoric activity measurements is determined from a dataset of measurements obtained from the subject using a mobile device. The qualimetric activity parameter is compared to a reference and the disease or disorder is thereby assessed. A method identifying whether a subject will benefit from a therapy for a cognition and movement disease or disorder is also disclosed. The method can be carried out with a mobile device having a processor, a sensor and a database as well as software that carries out the method. Also disclosed is a system having a mobile device with a sensor and a remote device having a processor and a database and software that carries out the method for assessing a cognition and movement disease or disorder.

Digital qualimetric biomarkers for cognition and movement diseases or disorders

A method for automatically assessing information processing speed in a test subject is disclosed. In the inventive method, a first qualimetric activity parameter for sensorial transmission, cognition and motoric output activity is determined and a second qualimetric activity parameter for sensorial transmission and motoric output activity is determined. A third qualimetric activity parameter for cognition is determined by comparing the first and the second qualimetric activity parameters to each other, and the information processing speed in the test subject is assessed based on the first, second and third qualimetric activity parameters. The information processing speed can be determined by comparing the determined qualimetric activity parameters to a reference and the subject's cognitive impairment can then be determined from the processing speed. The inventive method can be computer implemented. A mobile device or system for carrying out the disclosed methods is also disclosed.

Digital qualimetric biomarkers for determining information processing speed

Display screen with transitional graphical user interface

The present disclosure relates to the field of diagnostics, specifically, to a method of identifying progressing multiple sclerosis (MS) in a subject. At least one performance parameter is determined from a dataset of activity measurements obtained from the subject using a mobile device, and the performance parameter is compared to a reference, whereby a subject with progressing MS will be identified. Also disclosed is a method of recommending an anti-CD20 antibody therapy against MS that includes the steps just mentioned and the further step of recommending the anti-CD20 antibody therapy if the subject suffers from progressing MS. Also disclosed is a mobile device having a processor, at least one sensor and a database as well as software which is tangibly embedded to the device and, when running on said device, carries out the method of this disclosure as well as the use of such a device for identifying a subject suffering from progressing MS.

Digital biomarkers for progressing MS

Growing community of inventors

Basel, Switzerland

Christian Gossens